Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion.

In addition to its calciotropic function, the secosteroid 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) has potent nonclassical effects. In particular, local production of 1,25D(3) catalyzed by the enzyme 1alpha-hydroxylase (1alpha-OHase) may act as an autocrine/paracrine immunomodulatory mechanism. To investigate the significance of this in vascular tissue the expression and function of 1alpha-OHase in human endothelial cells was characterized. Immunohistochemical and in situ hybridization analyses show, for the first time, the presence of 1alpha-OHase mRNA and protein in endothelial cells from human renal arteries as well as postcapillary venules from lymphoid tissue. Reverse transcription-PCR and Western blot analyses confirmed the presence of 1alpha-OHase in primary cultures of human umbilical vein endothelial cells (HUVEC). Enzyme activity in HUVEC (318 +/- 56 fmoles 1,25(OH)(2)D(3)/hr/mg protein) increased after treatment with tumor necrosis factor-alpha (1054 +/- 166, P < 0.01), lipopolysaccharide (1381 +/- 88, P < 0.01), or forskolin (554 +/- 56, P < 0.05). Functional studies showed that exogenously added 1,25(OH)(2)D(3) or its precursor, 25-hydroxyvitamin D(3) (25(OH)D(3)), significantly decreased HUVEC proliferation after 72 h of treatment (33% and 11%, respectively). In addition, after 24 h treatment, both 1,25(OH)(2)D(3) and 25(OH)D(3) increased the adhesion of monocytic U937 cells to HUVEC (159% and 153%, respectively). These data indicate that human endothelia are able to produce active vitamin D. The rapid induction of endothelial 1alpha-OHase activity by inflammatory cytokines suggests a novel autocrine/paracrine role for the enzyme, possibly as a modulator of endothelial cell adhesion.

[1]  J. Adams,et al.  Vitamin D as a Cytokine and Hematopoetic Factor , 2001, Reviews in Endocrine and Metabolic Disorders.

[2]  A. Zinsmeister,et al.  Soft tissue calcification in pediatric patients with end-stage renal disease , 1991, Pediatric Nephrology.

[3]  M. Holick,et al.  25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue , 2001, The Lancet.

[4]  J. McNeal,et al.  Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. , 2001, Cancer research.

[5]  A. Howie,et al.  Extrarenal Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase1 , 2001 .

[6]  J. Flanagan,et al.  25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. , 2001, Lancet.

[7]  Simon C Watkins,et al.  Nitric Oxide Induces Angiogenesis and Upregulates αvβ3 Integrin Expression on Endothelial Cells , 2000 .

[8]  N. Bundred,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Angiogenesis In Vitro and In Vivo , 2000 .

[9]  R. Elashoff,et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. , 2000, The New England journal of medicine.

[10]  H. Pols,et al.  Anti-tumor effects of 1,25-dihydroxyvitamin D3 and vitamin D analogs. , 2000, Current pharmaceutical design.

[11]  Alex J. Brown,et al.  Mechanisms for the selective actions of vitamin D analogues. , 2000, Current pharmaceutical design.

[12]  N. Bundred,et al.  1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. , 2000, Circulation research.

[13]  Simon C Watkins,et al.  Nitric oxide induces angiogenesis and upregulates alpha(v)beta(3) integrin expression on endothelial cells. , 2000, Microvascular research.

[14]  D. Feldman,et al.  Editorial/Mini-Review: Vitamin D and Prostate Cancer. , 2000, Endocrinology.

[15]  A. Howie,et al.  Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase in the Human Kidney , 1999 .

[16]  C. Garland,et al.  Calcium and Vitamin D: Their Potential Roles in Colon and Breast Cancer Prevention , 1999, Annals of the New York Academy of Sciences.

[17]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[18]  N. Weigel,et al.  Vitamin D and Prostate Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[19]  M. Tassabehji,et al.  Novel Mutations in the 1α‐Hydroxylase (P450c1) Gene in Three Families with Pseudovitamin D–Deficiency Rickets Resulting in Loss of Functional Enzyme Activity in Blood‐Derived Macrophages , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium. , 1999, Endocrinology.

[21]  D. Wheeler,et al.  Fibronectin augments monocyte adhesion to low-density lipoprotein-stimulated mesangial cells. , 1999, Kidney international.

[22]  H. DeLuca,et al.  Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.

[23]  J. Loscalzo,et al.  Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.

[24]  T. Chen,et al.  Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  N. Bell.  Renal and Nonrenal 25‐Hydroxyvitamin D‐1α‐Hydroxylases and Their Clinical Significance , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  W. Miller,et al.  Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. , 1997, Molecular endocrinology.

[27]  K. Watson,et al.  Active serum vitamin D levels are inversely correlated with coronary calcification. , 1997, Circulation.

[28]  H. Cross,et al.  Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: Expression of 25-hydroxyvitamin D3-1α-hydroxylase activity and regulation of sidechain metabolism , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  D. Feldman,et al.  Immunomodulatory and cell differentiation effects of vitamin D. , 1997 .

[30]  J. Adams,et al.  Extrarenal production and action of active vitamin D metabolites in human lymphoproliferative diseases. , 1997 .

[31]  H. Cross,et al.  Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1alpha-hydroxylase activity and regulation of side-chain metabolism. , 1997, The Journal of steroid biochemistry and molecular biology.

[32]  A. Mackay,et al.  Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[33]  M. Daha,et al.  1,25-dihydroxycholecalciferol enhances the expression of MHC class II antigens and intercellular adhesion molecule-1 by human renal tubular epithelial cells. , 1996, The Journal of urology.

[34]  T. Maniatis,et al.  Transcriptional regulation of endothelial cell adhesion molecules : NF-icB and cytokine-inducible enhancers , 2004 .

[35]  C. Mathieu,et al.  Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analogs. , 1995, European journal of endocrinology.

[36]  J. Adams,et al.  Coordinate regulation of nitric oxide and 1,25-dihydroxyvitamin D production in the avian myelomonocytic cell line HD-11. , 1995, Endocrinology.

[37]  E. Hughson,et al.  Transfection of vitamin D receptor cDNA into the monoblastoid cell line U937. The role of vitamin D3 in homotypic macrophage adhesion. , 1994, Journal of immunology.

[38]  D. Adams,et al.  Leucocyte-endothelial interactions and regulation of leucocyte migration , 1994, The Lancet.

[39]  S. Teitelbaum,et al.  1 alpha,25-dihydroxyvitamin D3 up-regulates expression of the osteoclast integrin alpha v beta 3. , 1993, The Journal of biological chemistry.

[40]  A. Zinsmeister,et al.  Soft tissue calcification in pediatric patients with end-stage renal disease. , 1990 .

[41]  M. Haussler,et al.  Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. , 1989, The Journal of clinical investigation.

[42]  P. Elias,et al.  1,25-Dihydroxyvitamin D production and receptor binding in human keratinocytes varies with differentiation. , 1988, The Journal of biological chemistry.

[43]  H. Koeffler,et al.  25-Hydroxyvitamin D3 metabolism by lipopolysaccharide-stimulated normal human macrophages. , 1987, The Journal of clinical endocrinology and metabolism.

[44]  J. Adams,et al.  Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. , 1983, The Journal of clinical investigation.

[45]  A. Norman,et al.  Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. , 1981, The New England journal of medicine.

[46]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.